Antonelli, Flaminia
 Distribuzione geografica
Continente #
NA - Nord America 170
EU - Europa 96
AS - Asia 22
AF - Africa 6
Totale 294
Nazione #
US - Stati Uniti d'America 169
IT - Italia 26
SE - Svezia 21
IE - Irlanda 17
CN - Cina 8
DE - Germania 6
IN - India 6
CI - Costa d'Avorio 5
FI - Finlandia 5
GB - Regno Unito 5
FR - Francia 4
SG - Singapore 4
NL - Olanda 3
RU - Federazione Russa 3
BE - Belgio 2
HK - Hong Kong 2
AT - Austria 1
CH - Svizzera 1
HU - Ungheria 1
IL - Israele 1
JP - Giappone 1
ME - Montenegro 1
PA - Panama 1
SC - Seychelles 1
Totale 294
Città #
Chandler 45
Ashburn 29
New York 24
Dublin 16
Chicago 12
Milan 10
Beijing 7
Bremen 6
Abidjan 5
Pune 5
Helsinki 4
Rome 4
Amsterdam 3
Bologna 3
London 3
Ragusa 3
Boydton 2
Brussels 2
Edinburgh 2
Hong Kong 2
Paris 2
White Salmon 2
Anchorage 1
Andover 1
Anniston 1
Besançon 1
Boston 1
Bracke 1
Budapest 1
Busto Arsizio 1
Catania 1
Dresden 1
Kochi 1
Lappeenranta 1
Marseille 1
Panama City 1
Piansano 1
Podgorica 1
Princeton 1
Tokyo 1
Vienna 1
Washington 1
Wenzhou 1
Zurich 1
Totale 213
Nome #
Therapeutic impact and management of persistent head and neck atopic dermatitis in dupilumab-treated patients 51
Similar Levels of Efficacy of Two Different Maintenance Doses of Adalimumab on Clinical Severity and Quality of Life of Patients with Hidradenitis Suppurativa 39
Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy 35
Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy 33
Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy 28
Alopecia Areata Occurring after COVID-19 Vaccination: A Single-Center, Cross-Sectional Study 28
Investigational systemic drugs for moderate to severe plaque psoriasis: What's new? 21
Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy 21
Beneficial effects of upadacitinib on alopecia areata associated with atopic dermatitis: A multicenter retrospective study 14
Successful response to upadacitinib in the treatment of atopic dermatitis lesions involving sensitive and visible areas resistant to dupilumab treatment 13
Dupilumab-associated ocular adverse events are predicted by low tear break-up time and correlate with high IL-33 tear concentrations in patients with atopic dermatitis 10
Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation 9
Infectious adverse events in patients with atopic dermatitis treated with baricitinib 1
Totale 303
Categoria #
all - tutte 2.007
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.007


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20227 0 0 0 0 0 0 0 0 0 3 2 2
2022/2023161 3 21 12 21 11 14 8 20 28 13 9 1
2023/2024135 2 25 14 26 14 33 9 3 6 3 0 0
Totale 303